TransMedics (TMDX) Common Equity (2018 - 2026)

TransMedics' Common Equity history runs 9 years deep, the most recent figure standing at $494.0 million for Q1 2026.

• In Q1 2026, Common Equity rose 85.5% year-over-year to $494.0 million; the TTM figure through Mar 2026 stood at $494.0 million (up 85.5% YoY), while the FY2025 annual figure was $473.1 million, up 106.95% from the prior year.
• Common Equity was $494.0 million for Q1 2026 at TransMedics, up from $473.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $494.0 million in Q1 2026 to a low of $50.9 million in Q2 2022.
• Historically, Common Equity has averaged $222.5 million across 5 years, with a median of $189.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Common Equity slumped 42.78% in 2022, then surged 221.52% in 2023.
• A 5-year view of Common Equity shows it stood at $187.4 million in 2022, then declined by 26.78% to $137.2 million in 2023, then jumped by 66.62% to $228.6 million in 2024, then soared by 106.95% to $473.1 million in 2025, then climbed by 4.42% to $494.0 million in 2026.
• The last three Common Equity figures came in at $494.0 million (Q1 2026), $473.1 million (Q4 2025), and $355.2 million (Q3 2025), per Business Quant data.